Catalyst Market Capitalization from 2010 to 2025
| CPRX Stock | USD 24.84 0.31 1.23% |
Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 311.4 M or Operating Income of 204.9 M, as well as many indicators such as Price To Sales Ratio of 4.78, Dividend Yield of 0.0 or PTB Ratio of 3.23. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.
Catalyst | Market Capitalization |
Latest Catalyst Pharmaceuticals' Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Catalyst Pharmaceuticals over the last few years. It is Catalyst Pharmaceuticals' Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 3.12 B | 10 Years Trend |
|
Market Cap |
| Timeline |
Catalyst Market Capitalization Regression Statistics
| Arithmetic Mean | 707,562,064 | |
| Geometric Mean | 246,596,580 | |
| Coefficient Of Variation | 130.05 | |
| Mean Deviation | 743,389,454 | |
| Median | 335,487,724 | |
| Standard Deviation | 920,183,396 | |
| Sample Variance | 846737.5T | |
| Range | 2.6B | |
| R-Value | 0.85 | |
| Mean Square Error | 254814.1T | |
| R-Squared | 0.72 | |
| Significance | 0.000033 | |
| Slope | 163,901,557 | |
| Total Sum of Squares | 12701062.2T |
Catalyst Market Capitalization History
About Catalyst Pharmaceuticals Financial Statements
Catalyst Pharmaceuticals investors use historical fundamental indicators, such as Catalyst Pharmaceuticals' Market Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.